The anti-CD38 chitosan nanoparticles facilitated endocytosis-mediated uptake of CD38, which enhanced BTZ’s proteasome-inhibitory activity and specificity and resulted in a low toxicity profile to represent a promising therapy for MM. This evidence concerns the gene CD38 and Miyoshi myopathy.